Photodynamic therapy opportunities for the treatment of erythroplasia of Queyrat

The review is dedicated to the analysis of the effectiveness of the treatment of erythroplasia of Queyrat (EQ) using photodynamic therapy (PDT). Particular attention is paid to the relationship between EQ and human papillomavirus (HPV) infection. The data of various researchers are presented, confirming the correlation between the development of the EQ and the HPV infection, however, it is noted that due to the small number of studies it is difficult to draw reliable conclusions on the presence and strength of this connection. The mechanisms of PDT involved in the implementation of both the antitumor effect in the treatment of EQ and the antiviral effect against HPV are considered. The data of 12 clinical studies and observations of the results of PDT of the EQ conducted in recent years are analyzed. An analysis of literature data showed that in the treatment of EQ, one of the two photosensitizers is usually used locally: 5-aminolevulinic acid or 5-aminolevulinic acid methyl ester. The treatment parameters in all the analyzed studies were similar: exposure to the ointment for 3–5 hours followed by irradiation with a light dose of 37–105 J/cm². The number of PDT courses in different studies varied from 1 to 19. The effectiveness of treatment varied widely in different studies and clinical observations. Most studies have demonstrated high efficacy of PDT with complete regression in 36–83% (100% in one study) and a relapse-free follow-up period of up to 51 months. However, there were also individual clinical observations of patients in whom the treatment with the method of PDT was ineffective. It is possible that the described results were associated with improperly selected regimes of PDT or a large lesion area. Most authors especially note a very good cosmetic effect and a complete absence of scars after the treatment. Thus, PDT is an effective and promising method for the treatment of EQ that requires, however, a more thorough development of the application regimen and a deeper study of the antitumor and antiviral components of the mechanism of action.

5-aminolevulinic acid, aminolaevulinic acid methyl ester, photodynamic therapy, erythroplasia of Queyrat

1. Barnholtz-Sloan J. S., Maldonado J. L., Powsang J., Giuliano A. R. Incidence trends in primary malignant penile cancer, Urol Oncol, 2007, vol. 25, pp. 361–7.

2. Micali G., Nasca M. R., Innocenzi D., Schwartz R. A. Penile cancer, J Am Acad Dermatol, 2006, vol. 54 (3), pp. 369–94.

3. DelLosada J. P.,Ferré A.,Román B. S.,VieiraV.,Fonseca E. Erythroplasia of Queyrat with Urethral Involvement: Treatment with Carbon Dioxide Laser Vaporization, Dermatologic Surgery, 2005, vol. 31 (11), pp. 1454–1457. doi:10.2310/6350.2005.31217

4. Horenblas S., Von Krogh G., Cubilla A. L., Dillner J., Meijer C. J., Hedlund P. O. Squamous cell carcinoma of the penis: premalignant lesions, Scand J Urol Nephrol, 2000, suppl. 205, pp. 187–188.

5. Gross G., Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts, Med Microbiol Immunol, 2004, vol. 193, – pp. 35–44.

6. Liu Y., Wang J., Wang X., Fang K. Detecting HPV DNA in tissue of epidermal neoplasms, Zhongguo yi xue ke xue yuan xue bao, 1997, vol. 19 (1), pp. 64–6. [in Chinese]

7. Fismen S., Grimstad Ø. Two cases of erythroplasia of Queyrat with persistent post-treatment inflammation after histological remission of epithelial dysplasia, Eur J Dermatol, 2015, vol. 25 (4), pp. 348–9. doi:10.1684/ejd.2015.2568

8. Wieland U., Jurk S., Weissenborn S., Krieg T., Pfister H., Ritzkowsky A. Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ, J Invest Dermatol, 2000, vol. 115 (3), pp. 396–401.

9. Wang J. B., Man X. H., Liu Y. H., Fang K. Detecting HPV DNA in tissues of external genital squamous cell carcinoma in situ by PCRRFLP technique, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2003, vol. 25 (6), pp. 667–70. [in Chinese]

10. Goette D. K., Carson T. E. Erythroplasia of Queyrat: treatment with topical 5-fluorouracil, Cancer, 1976, vol. 38, pp. 1498–1502.

11. Schellhammer P. F., Jordan G. H., Robey E. L. Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum, Urol Clin North Am, 1992, vol. 19, pp. 131–142.

12. Mikhail G. R. Cancers, precancers, and pseudocancers on the male genitalia: a review of clinical appearances, histopathology, and management, J Dermatol Surg Oncol, 1980, vol. 6, pp. 1027–1035.

13. Mohs F. E., Snow S. N., Larson P. O. Mohs micrographic surgery for penile tumors, Urol Clin North Am, 1992, vol. 19, pp. 291–304.

14. Van Bezooijen B. P., Horenblas S., Meinhardt W., Newling D. W. Laser therapy for carcinoma in situ of the, J Urol, 2001, vol. 166, pp. 1670–1671.

15. Yamaguchi Y., Hata H., Imafuku K., Kitamura S., Shimizu H. A case of erythroplasia of Queyrat successfully treated with combination carbon dioxide laser vaporization and surgery, J Eur Acad Dermatol Venereol, 2016, vol. 30 (3), pp. 497–8. doi:10.1111/jdv.12888

16. Sonnex T. S., Ralfs I. G., Plaza de Lanza M., Dawber R. P. Treatment of erythroplasia of Queyrat with liquid nitrogen cryosurgery, Br J Dermatol, 1982, vol. 106, pp. 581–584.

17. Blank A. A., Schnyder U. W. Soft X-ray therapy in Bowen’s disease and erythroplasia of Queyrat, Dermatologica, 1985, vol. 171, pp. 89–94.

18. Schmitz L., Bierhoff E., Dirschka T. Optical coherence tomography imaging of erythroplasia of Queyrat and treatment with imiquimod 5% cream: a case report, Dermatology, 2014, vol. 228 (1), pp. 24–6. doi: 10.1159/000354652

19. Deen K., Burdon-Jones D. Imiquimod in the treatment of penile intraepithelial neoplasia: An update, Australas J Dermatol, 2017, vol. 58 (2), pp. 86–92. doi: 10.1111/ajd.12466

20. Maisch T. Resistance in antimicrobial photodynamic inactivation of bacteria, Photochem. Photobiol. Sci., 2015, vol. 14, pp. 15181526.

21. Wiehe A., O’Brien J. M., Senge M. O. Trends and targets in antiviral phototherapy, Photochemical & Photobiological Sciences, 2019. doi:10.1039/c9pp00211a

22. Shishkova N., Kuznetsova O., Berezov T. Photodynamic Therapy for Gynecological Diseases and Breast Cancer, Cancer Biol Med, 2012, vol. 9 (1), pp. 9–17. doi: 10.3969/j.issn.2095–3941.2012.01.002

23. Dąbrowski J. M., Arnaut L. G. Photodynamic therapy (PDT) of cancer: from local to systemic treatment, Photochem. Photobiol. Sci., 2015, vol. 14, pp. 1765–1780.

24. Kwitniewski M., Juzeniene A., Glosnicka R., Moan J. Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy?, Photochem. Photobiol. Sci., 2008, vol. 8, pp. 1011–1017.

25. Castano A. P., Mroz P., Hamblin M. R. Photodynamic therapy and anti-tumour immunity, Nat. Rev. Cancer, 2006, vol. 6, pp. 535–545.

26. Ogilby P. R. Singlet oxygen: there is indeed something new under the sun, Chem. Soc. Rev., 2010, vol. 39, pp. 3181–3209.

27. Kanofsky J. R. Measurement of Singlet-Oxygen In Vivo: Progress and Pitfalls, Photochem. Photobiol., 2011, vol. 87, pp. 14–17.

28. Jarvi M. T., Niedre M. J., Patterson M. S., Wilson B. C. The Influence of Oxygen Depletion and Photosensitizer Triplet-state Dynamics During Photodynamic Therapy on Accurate Singlet Oxygen Luminescence Monitoring and Analysis of Treatment Dose Response, Photochem. Photobiol., 2011, vol. 87, pp. 223–234.

29. Via L. D., Magno S. M. Photochemotherapy in the Treatment of Cancer, Curr. Med. Chem., 2001, vol. 8, pp. 1405–1418.

30. Sobotta L., Skupin-Mrugalska P., Mielcarek J., Goslinski T., Balzarini J. Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles, Mini-Rev. Med. Chem., 2015, vol. 15, pp. 503–521.

31. Wainwright M. Photoinactivation of viruses, Photochem. Photobiol. Sci., 2004, vol. 3, pp. 406–411.

32. Maranda E. L., Nguyen A. H., Lim V. M., Shah V. V., Jimenez J. J. Erythroplasia of Queyrat treated by laser and light modalities: a systematic review, Lasers in Medical Science, 2016, vol. 31 (9), pp. 1971–1976. doi:10.1007/s10103–016–2005–9

33. Paoli J., Bratel A., Löwhagen G., Stenquist B., Forslund O., Wennb erg A. Penile Intraepithelial Neoplasia: Results of Photodynamic Therapy, Acta Dermato-Venereologica, 2006, vol. 86 (5), pp. 418–421. doi:10.2340/00015555–0130

34. Filonenko E. V., Kaprin A. D., Alekseev B.YA., Urlova A. N. Clinical observation of successful photodynamic therapy of a patient with erythroplasia of Queyrat. Fotodinamicheskaya terapiya i fotodiagnostika, 2014, vol. 3, no. 2, pp. 28–30. (in Russian)

35. Varma S., Holt P. J. A., Anstey A. V. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale, British Journal of Dermatology, 2000, vol. 142 (4), pp. 825–826. doi:10.1046/j.1365–2133.2000.03441.x

36. Jia Q. N., Nguyen G. H., Fang K., Jin H. Z., Zeng Y. P. Development of squamous cell carcinoma from erythroplasia of Queyrat following photodynamic therapy, Eur J Dermatol, 2018, vol. 28 (3), pp. 405–406. doi: 10.1684/ejd.2018.3272

37. Lee M. R., Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy, Australasian Journal of Dermatology, 2005, vol. 46 (3), pp. 196–198. doi:10.1111/j.1440–0960.2005.00179.x

38. Calzavara-Pinton P. G., Rossi M. T., Sala R., The Italian Group for Photodynamic Therapy. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 2: Oncologic and infectious indications, Photochemical & Photobiological Sciences, 2013, vol. 12 (1), pp. 158–65. doi:10.1039/c2pp25125f

39. Fai D., Romano I., Cassano N., Vena G. A. Methyl-aminolevulinate photodynamic therapy for the treatment of erythroplasia of Queyrat in 23 patients, Journal of Dermatological Treatment, 2013, vol. 23 (5), pp. 330–332. doi:10.3109/09546634.2011.577405

40. Skroza N., La Viola G., Pampena R., Proietti I., Bernardini N., Tolino E., Annetta A., Zuber S., Balduzzi V., Potenza C. Erythroplasia of Queyrat treated with methyl aminolevulinate-photodynamic therapy (MAL-PDT): case report and review of the literature, G Ital Dermatol Venereol, 2016.

41. Wang X.-L., Wang H.-W., Guo M.-X., Xu S.-Z. Treatment of skin cancer and pre-cancer using topical ALA-PDT – A single hospital experience, Photodiagnosis and Photodynamic Therapy, 2008, vol. 5 (2), pp. 127–133. doi:10.1016/j.pdpdt.2008.05.003

42. Feldmeyer L., Krausz-Enderlin V., Töndury B., Hafner J., French L. E., Hofbauer G. F. L. Methylaminolaevulinic Acid Photodynamic Therapy in the Treatment of Erythroplasia of Queyrat, Dermatology, 2011, vol. 223 (1), pp. 52–56. doi:10.1159/000330328

43. Park J.-Y., Kim S. J., Kim Y. C. Erythroplasia of Queyrat refractory to photodynamic therapy, Clinical and Experimental Dermatology, 2012, vol. 37 (7), pp. 795–797. doi:10.1111/j.1365-2230.2012.04361.x

44. Vasilevskaya E. A., Vardanyan K. L., Dzybova E. M. The experience of using photodynamic therapy with methylaminolevulinic acid in erythroplasia of Queyrat, Klinicheskaya dermatologiya i venerologiya, 2015, no. 5, pp. 98–103. (in Russian)